CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BI 474121Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1815 NHANES smell and taste tests Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D000370 Ageusia NIH 1.00
D000857 Olfaction Disorders NIH 0.27
D014777 Virus Diseases NIH 0.12
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0000224 Hypogeusia HPO 1.00
HP:0000458 Anosmia HPO 0.27

There is one clinical trial.

Clinical Trials

1 A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 474121 Administered as Oral Solution and Tablets to Healthy Male Subjects (SRD Part), and a Randomised, Open-label, Single-dose, Three-way Cross-over Bioavailability Comparison of BI 474121 as Tablet Versus Oral Solution and Tablet With and Without Food (BA Part)

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 474121 in healthy male subjects following oral administration of single rising doses.

NCT04194645 Healthy Drug: BI 474121 Drug: Placebo

Primary Outcomes

Measure: Percentage of subjects with drug-related adverse events (Single-rising dose (SRD) part)

Time: Up to 15 days

Measure: BA part: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)

Time: Up to 96 hours

Measure: BA part: Cmax (maximum measured concentration of the analyte in plasma)

Time: Up to 96 hours

Secondary Outcomes

Measure: SRD part: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)

Time: Up to 96 hours

Measure: SRD part: Cmax (maximum measured concentration of the analyte in plasma)

Time: Up to 96 hours

Measure: BA part: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to 96 hours

No related HPO nodes (Using clinical trials)